Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

We’ll be back on Monday morning with more fresh content!

The short-term study is believed to be the first to evaluate both interventions combined for people with mental illness.

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery ...

A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with ...

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery at a cash price that is up to 70% off the list price.

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...